Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

1.15
+0.03002.68%
Post-market: 1.13-0.0200-1.74%17:13 EDT
Volume:534.22K
Turnover:608.67K
Market Cap:103.59M
PE:-1.02
High:1.17
Open:1.12
Low:1.10
Close:1.12
Loading ...

Immunic's Cash And Cash Equivalents As Of September 30, Were $59.1M, Expected To Provide Cash Runway Into Q3 Of 2025

Benzinga
·
07 Nov 2024

Immunic Q3 2024 GAAP EPS $(0.24) Misses $(0.22) Estimate

Benzinga
·
07 Nov 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
07 Nov 2024

Immunic Q3 Basic EPS USD -0.24

THOMSON REUTERS
·
07 Nov 2024

Immunic Q3 Operating Expenses USD 25.726 Million

THOMSON REUTERS
·
07 Nov 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire
·
07 Nov 2024

Immunic Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

BRIEF-Immunic To Announce Financial Results For The Third Quarter

Reuters
·
31 Oct 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

THOMSON REUTERS
·
31 Oct 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

PR Newswire
·
31 Oct 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November

PR Newswire
·
29 Oct 2024

Promising Phase 3 Trial Results and Strategic Insights Drive Buy Rating for Vidofludimus Calcium

TIPRANKS
·
24 Oct 2024

Immunic late-stage program for lead asset to proceed as planned

seekingalpha
·
23 Oct 2024

Immunic Shares up 11.3% After Co Reports Interim Late-Stage Data for Multiple Sclerosis Drug

THOMSON REUTERS
·
22 Oct 2024

Immunic Shares Up 12% on Positive MS Drug Analysis

Dow Jones
·
22 Oct 2024

Immunic Shares Advance on Positive Outcome From Interim Analysis of Potential MS Treatment

MT Newswires Live
·
22 Oct 2024